Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New device may predict kidney recovery in ICU patients

NCT ID NCT02812784

Diagnosis Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the Nephrocheck™ device can predict if early acute kidney injury will reverse within 72 hours in patients with septic shock. Researchers enrolled 184 adults in the ICU and measured the device's accuracy. The goal is to help doctors decide who might recover without aggressive treatments like dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nephrocheck™ device
What this could lead to
If successful, this could help doctors quickly identify which patients with septic shock will recover kidney function without needing dialysis.
What could go wrong
This is a completed study with 184 participants, so results are available but may not apply to all patients. The device is a diagnostic tool, not a treatment, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

184 people

The number who actually took part.

Started

Sep 2015

Finished

Feb 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 or over * Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines * AKI, characterized by a KDIGO score ≥ 1 * Social security coverage Exclusion Criteria: * AKI requiring emergency RRT (in the critical care physician's opinion). * Anuria * Stage 4-5 chronic kidney failure with a GFR below 30 ml/min. * Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.) * Obstructive AKI * Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis) * Pregnancy or breastfeeding * Legal guardianship or lack of social security coverage. * Cardiocirculatory arrest * Life expectancy \<48 hours. * Child C cirrhosis * Prior occurrence of AKI during the current hospital stay * Transplantation * Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heading are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heading

Contacts and locations

Locations

  • CH Avranches-Granville

    Avranches, 50300, France

  • CH Cahors

    Cahors, 46000, France

  • CH Dax

    Dax, 40100, France

  • CH Marc Jacquet

    Melun, 77000, France

  • CH Paris-Saint Joseph

    Paris, 75, France

  • CH Salon-de-provence

    Salon-de-Provence, 13300, France

  • CH de Mont-de-Marsan

    Mont-de-Marsan, 40000, France

  • CHU Amiens

    Amiens, 80054, France

  • CHU Montpellier

    Montpellier, 34172, France

  • CHU Poitiers

    Poitiers, 86000, France

  • CHU Saint-Etienne

    Saint-Etienne, 42000, France